Clinical outcomes of de novo metastatic HER2-positive inflammatory breast cancer

In conclusion, patients with de novo HER2-positive mIBC who undergo surgery have favorable outcomes. More than half of patients received systemic and local therapy with good locoregional control and prolonged survival, suggesting a potential role for local therapy.PMID:37268625 | DOI:10.1038/s41523-023-00555-w

Source: Cancer Control - June 2, 2023 Category: Cancer & Oncology Authors: Ana C Garrido-Castro Meredith M Regan Samuel M Niman Faina Nakhlis Claire Remolano Jennifer M Rosenbluth Caroline Block Laura E Warren Jennifer R Bellon Eren Yeh Beth T Harrison Elizabeth Troll Nancy U Lin Sara M Tolaney Beth Overmoyer Filipa Lynce Source Type: research